Research Highlights:

  • Mavacamten, a new investigational cardiac medication, may improve heart function for people with thickened heart muscle leading to obstructed blood flow through the heart, a condition known as obstructive hypertrophic cardiomyopathy.
  • The treatment appears to improve heart structure, reduce cardiac filling pressures (decrease measures of stiffness) and restore normal mitral valve motion.
  • Currently, treatment for obstructive hypertrophic cardiomyopathy focuses on symptom relief, and this medication has been shown in a recently published Phase 3, placebo-controlled study to relieve symptoms; this additional analysis of the data demonstrates that mavacamten also addresses the underlying causes of the condition.

Embargoed until 4 a.m. CT/5 a.m. ET Monday, Nov. 9, 2020

DALLAS, Nov. 9, 2020 — The new, investigational heart medication mavacamten may improve key structural abnormalities of obstructive hypertrophic cardiomyopathy, a condition characterized by thickened heart muscle that obstructs pumping of blood through the heart, according to research from the Phase 3 EXPLORER-HCM trial, to be presented at the American Heart Association’s Scientific Sessions 2020. The meeting will be held virtually, Friday, November 13 – Tuesday, November 17, 2020, and is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science for health care worldwide.

Hypertrophic cardiomyopathy affects 1 in 500 people and is caused by genes expressed in the heart muscle that trigger the walls of the heart chamber (the left ventricle) to contract harder and thicken more than normal. In obstructive hypertrophic cardiomyopathy, the wall between the two bottom chambers of the heart thicken, and the walls of the chamber that pumps blood can also become stiff. This may block or reduce the flow of blood from the left ventricle of the heart to the aorta. Current treatments for hypertrophic cardiomyopathy focus on relieving symptoms, such as chest pain and shortness of breath - especially with physical exertion, fatigue, abnormal heart rhythms, dizziness, fainting (syncope) and/or swelling in the ankles, feet, legs, abdomen and veins in the neck.

The EXPLORER-HCM clinical trial is an international, double-blind, placebo-controlled, phase three trial to evaluate the efficacy of mavacamten for adults with symptomatic obstructive hypertrophic cardiomyopathy. Recently, the primary results of the trial were announced, and mavacamten was shown to improve symptoms among those with obstructive hypertrophic cardiomyopathy. Among 244 patients (average age 58) who completed the trial, mavacamten led to significant improvement in reducing obstruction to flow through the heart, improving exercise capacity and symptoms.

This study is an additional analysis of data from the EXPLORER-HCM trial. Researchers found that mavacamten also reduces the size of the enlarged left atrium of the heart, decreases elevated filling pressures (reduces measures of stiffness) and restores normal mitral valve motion.

Participants with obstructive hypertrophic cardiomyopathy were randomly assigned to receive either mavacamten (in doses ranging from 2.5 to 15 mg) or a placebo daily for 30 weeks. Cardiac testing and patient evaluation were conducted every two-to-four weeks during the study period.

In this study, analyses of serial echocardiograms (ultrasounds of the heart) were reviewed to investigate the effect mavacamten had on additional specific measures of the heart’s structure and function. Data from the analyses indicates 30-weeks of treatment with mavacamten led to improvement in measurements of the left ventricle’s wall thickness and markers of blood flow through the heart. Additionally, abnormal motion of the mitral valve, which often leads to obstructive blood flow, and mitral valve regurgitation were resolved in most patients.

“Improvement in the key echocardiographic features of hypertrophic cardiomyopathy supports the hypothesis that mavacamten can be used as a disease-specific therapy, which would be a significant advance in therapy for this population,” said Sheila M. Hegde, M.D., M.P.H., lead author of the study, a cardiovascular medicine specialist at Brigham and Women’s Hospital and an instructor in medicine at Harvard Medical School, both in Boston. “These findings reinforced and extended data from prior open label trials. Additional changes in measures of cardiac structure and function were also observed including reduction in the size of the left atrium. Together, these results reflect this medication’s impact on the underlying pathophysiology of hypertrophic cardiomyopathy. A long-term extension trial is ongoing and will provide additional insight on the long term-impact on cardiac structure and function.”

Co-authors are Theodore P. Abraham, M.D.; Daniel Jacoby, M.D.; Andrew Wang, M.D.; Carolyn Ho, M.D.; Wanying Li, Ph.D.; Amy J. Sehnert, M.D.; Scott D. Solomon, M.D.; Iacopo Olivotto, M.D.; and Steven J. Lester, M.D. Author disclosures are in the abstract.

The study was funded by MyoKardia. MyoKardia sponsors an American Heart Association initiative, which did not influence the science evaluation or acceptance of this abstract.

Note: Session: HF.APS.29 - Different Aspects of Hypertrophic Cardiomyopathy

Additional Resources:

Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers are available here, and the Association’s overall financial information is available here

About the American Heart Association

The American Heart Association is a leading force for a world of longer, healthier lives. With nearly a century of lifesaving work, the Dallas-based association is dedicated to ensuring equitable health for all. We are a trustworthy source empowering people to improve their heart health, brain health and well-being. We collaborate with numerous organizations and millions of volunteers to fund innovative research, advocate for stronger public health policies, and share lifesaving resources and information. Connect with us on, Facebook, Twitter or by calling 1-800-AHA-USA1.


For Media Inquiries and AHA Expert Perspective:

AHA News Media in Dallas: 214-706-1173;

Bridgette McNeill:

For Public Inquiries: 1-800-AHA-USA1 (242-8721) and